Mergers and Acquisitions

The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.

The acquisition marks a pivotal expansion for the company into the US market.

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.

Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.

Sterling is known as a global contract development and manufacturing organization, and their network spreads to a manufacturing site in Cramlington, United Kingdom, a recently GMP-licensed dedicated bioconjugation facility in Deeside, and a 111-acre site in Ringaskiddy, Ireland.

Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.

Biosynth has further strengthened its peptide division with the acquisition of Pepceuticals.

POINT is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

EMS is a leader in the cleanroom industry, delivering complete cleanroom monitoring and control solutions, services to customers, and ensuring quality by design from inception to process control.

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.

Novo Nordisk receives the full rights to develop and commercialize the lead program.

Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.

Zygel is the first and only pharmaceutically manufactured, synthetic cannabidiol that is formulated as a patient-protected permeation-enhanced gel for transdermal delivery.

The acquisition of the latter includes the company’s lead development asset INV-202, an oral CB1 inverse agonist which is designed to block the receptor protein CB1.

The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.

Novartis has completed its acquisition of biopharma company Chinook Therapeutics.

The initial collaboration between the two companies began in 2017 with an extension announced in 2021.

BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from this collaboration.

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.

The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.